浙江预防医学
浙江預防醫學
절강예방의학
ZHEJIANG JOURNAL OF PREVENTIVE MEDICINE
2014年
3期
242-244,262
,共4页
高华强%陈奇峰%金法祥%牛文柯
高華彊%陳奇峰%金法祥%牛文柯
고화강%진기봉%금법상%우문가
结核病%分枝杆菌%耐药性%监测
結覈病%分枝桿菌%耐藥性%鑑測
결핵병%분지간균%내약성%감측
Tuberculosis%Mycobacterium%Drug resistance%Monitoring
目的:掌握绍兴市肺结核患者耐药情况,为预防控制肺结核提供依据。方法对2010-2013年6月在绍兴市结核病定点医院就诊的涂阳肺结核患者痰标本分离株进行菌型鉴定,用药敏罗氏培养基进行药物敏感性试验,分析肺结核患者的耐药情况。结果在607份痰培养阳性标本中,总耐药率为20.26%,耐多药(MDR-TB)率12.85%,耐药率由高到低依次为INH、RFP、SM和EMB;初治总耐药率13.09%,耐多药率5.73%;复治总耐药率为50.00%,耐多药率42.37%。结论绍兴市结核分枝杆菌的总耐药率与全国平均水平相当,但复治病例耐多药率仍较高。
目的:掌握紹興市肺結覈患者耐藥情況,為預防控製肺結覈提供依據。方法對2010-2013年6月在紹興市結覈病定點醫院就診的塗暘肺結覈患者痰標本分離株進行菌型鑒定,用藥敏囉氏培養基進行藥物敏感性試驗,分析肺結覈患者的耐藥情況。結果在607份痰培養暘性標本中,總耐藥率為20.26%,耐多藥(MDR-TB)率12.85%,耐藥率由高到低依次為INH、RFP、SM和EMB;初治總耐藥率13.09%,耐多藥率5.73%;複治總耐藥率為50.00%,耐多藥率42.37%。結論紹興市結覈分枝桿菌的總耐藥率與全國平均水平相噹,但複治病例耐多藥率仍較高。
목적:장악소흥시폐결핵환자내약정황,위예방공제폐결핵제공의거。방법대2010-2013년6월재소흥시결핵병정점의원취진적도양폐결핵환자담표본분리주진행균형감정,용약민라씨배양기진행약물민감성시험,분석폐결핵환자적내약정황。결과재607빈담배양양성표본중,총내약솔위20.26%,내다약(MDR-TB)솔12.85%,내약솔유고도저의차위INH、RFP、SM화EMB;초치총내약솔13.09%,내다약솔5.73%;복치총내약솔위50.00%,내다약솔42.37%。결론소흥시결핵분지간균적총내약솔여전국평균수평상당,단복치병례내다약솔잉교고。
Objective To analyze the characteristics of drug resistance in tuberculosis patients in Shaoxing and provide scientific basis for prevention and control of tuberculosis.Methods All the sputum smear -positive specimens from tuberculosis patients in Shaoxing tuberculosis designated hospitals from 2010 to June 2013 had been done by susceptibility test using susceptibility Jensen medium.The situation of drug resistance in patients with pulmonary tuberculosis was analysed.Results In the 607 sputum culture -positive cases,the total resistance rate was 20.26%;the multi -drug resistance rate was 12.85%.The resistance rate in descending order was INH,RFP,SM and EMB.In new cases,the total resistance rate was 13.09%,and the multi-drug resistance rate was 5.73%;in retreated cases,the total resistance rate was 50.00%,and the multi-drug resistance rate was 42.37%.Conclusion In Shaoxing City,the total resistance rate of tuberculosis is consistent with the national average level,but the epidemic of MDR-TB is still very serious.